vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $140.7M, roughly 1.3× Purple Innovation, Inc.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -2.3%, a 1.6% gap on every dollar of revenue. On growth, Purple Innovation, Inc. posted the faster year-over-year revenue change (9.1% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-7.8M). Over the past eight quarters, Purple Innovation, Inc.'s revenue compounded faster (8.3% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
AVNS vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $140.7M |
| Net Profit | $-1.3M | $-3.2M |
| Gross Margin | 47.5% | 41.9% |
| Operating Margin | 1.4% | -1.6% |
| Net Margin | -0.7% | -2.3% |
| Revenue YoY | 0.7% | 9.1% |
| Net Profit YoY | 99.7% | 62.1% |
| EPS (diluted) | $-0.02 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $140.7M | ||
| Q3 25 | $177.8M | $118.8M | ||
| Q2 25 | $175.0M | $105.1M | ||
| Q1 25 | $167.5M | $104.2M | ||
| Q4 24 | $179.6M | $129.0M | ||
| Q3 24 | $170.4M | $118.6M | ||
| Q2 24 | $171.7M | $120.3M | ||
| Q1 24 | $166.1M | $120.0M |
| Q4 25 | $-1.3M | $-3.2M | ||
| Q3 25 | $-1.4M | $-11.7M | ||
| Q2 25 | $-76.8M | $-17.3M | ||
| Q1 25 | $6.6M | $-19.1M | ||
| Q4 24 | $-397.3M | $-8.5M | ||
| Q3 24 | $4.3M | $-39.2M | ||
| Q2 24 | $1.8M | $27.0K | ||
| Q1 24 | $-900.0K | $-50.2M |
| Q4 25 | 47.5% | 41.9% | ||
| Q3 25 | 48.4% | 42.8% | ||
| Q2 25 | 52.6% | 35.9% | ||
| Q1 25 | 53.6% | 39.4% | ||
| Q4 24 | 54.6% | 42.9% | ||
| Q3 24 | 54.5% | 29.7% | ||
| Q2 24 | 55.7% | 40.7% | ||
| Q1 24 | 57.1% | 34.8% |
| Q4 25 | 1.4% | -1.6% | ||
| Q3 25 | 0.1% | -10.2% | ||
| Q2 25 | -42.6% | -13.5% | ||
| Q1 25 | 6.1% | -13.9% | ||
| Q4 24 | -233.0% | -6.0% | ||
| Q3 24 | 7.0% | -39.5% | ||
| Q2 24 | 3.7% | -12.1% | ||
| Q1 24 | 2.4% | -19.3% |
| Q4 25 | -0.7% | -2.3% | ||
| Q3 25 | -0.8% | -9.9% | ||
| Q2 25 | -43.9% | -16.5% | ||
| Q1 25 | 3.9% | -18.4% | ||
| Q4 24 | -221.2% | -6.6% | ||
| Q3 24 | 2.5% | -33.1% | ||
| Q2 24 | 1.0% | 0.0% | ||
| Q1 24 | -0.5% | -41.8% |
| Q4 25 | $-0.02 | $0.03 | ||
| Q3 25 | $-0.03 | $0.11 | ||
| Q2 25 | $-1.66 | $0.16 | ||
| Q1 25 | $0.14 | $0.18 | ||
| Q4 24 | $-8.64 | $0.08 | ||
| Q3 24 | $0.09 | $0.36 | ||
| Q2 24 | $0.04 | $0.00 | ||
| Q1 24 | $-0.02 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $24.3M |
| Total DebtLower is stronger | $90.3M | $126.7M |
| Stockholders' EquityBook value | $778.2M | $-29.7M |
| Total Assets | $1.1B | $296.3M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $24.3M | ||
| Q3 25 | $70.5M | $32.4M | ||
| Q2 25 | $90.3M | $34.2M | ||
| Q1 25 | $97.0M | $21.6M | ||
| Q4 24 | $107.7M | $29.0M | ||
| Q3 24 | $89.0M | $23.4M | ||
| Q2 24 | $92.2M | $23.4M | ||
| Q1 24 | $75.8M | $34.5M |
| Q4 25 | $90.3M | $126.7M | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $70.7M | ||
| Q3 24 | $152.6M | $50.8M | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $-29.7M | ||
| Q3 25 | $778.0M | $-26.9M | ||
| Q2 25 | $776.3M | $-15.6M | ||
| Q1 25 | $839.4M | $1.3M | ||
| Q4 24 | $828.5M | $20.2M | ||
| Q3 24 | $1.2B | $28.0M | ||
| Q2 24 | $1.2B | $66.4M | ||
| Q1 24 | $1.2B | $65.5M |
| Q4 25 | $1.1B | $296.3M | ||
| Q3 25 | $1.1B | $302.1M | ||
| Q2 25 | $1.0B | $303.8M | ||
| Q1 25 | $1.1B | $293.8M | ||
| Q4 24 | $1.2B | $307.8M | ||
| Q3 24 | $1.7B | $309.3M | ||
| Q2 24 | $1.7B | $362.1M | ||
| Q1 24 | $1.7B | $382.1M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 3.50× | ||
| Q3 24 | 0.12× | 1.82× | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-5.8M |
| Free Cash FlowOCF − Capex | $21.3M | $-7.8M |
| FCF MarginFCF / Revenue | 11.8% | -5.5% |
| Capex IntensityCapex / Revenue | 3.8% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-5.8M | ||
| Q3 25 | $14.0M | $-968.0K | ||
| Q2 25 | $6.8M | $-4.0M | ||
| Q1 25 | $25.7M | $-23.1M | ||
| Q4 24 | $57.9M | $6.8M | ||
| Q3 24 | $23.0M | $1.1M | ||
| Q2 24 | $27.8M | $-8.9M | ||
| Q1 24 | $-8.0M | $-16.8M |
| Q4 25 | $21.3M | $-7.8M | ||
| Q3 25 | $7.0M | $-1.8M | ||
| Q2 25 | $-4.2M | $-7.0M | ||
| Q1 25 | $19.0M | $-25.3M | ||
| Q4 24 | $53.1M | $5.7M | ||
| Q3 24 | $20.0M | $101.0K | ||
| Q2 24 | $21.9M | $-11.0M | ||
| Q1 24 | $-12.1M | $-19.9M |
| Q4 25 | 11.8% | -5.5% | ||
| Q3 25 | 3.9% | -1.5% | ||
| Q2 25 | -2.4% | -6.6% | ||
| Q1 25 | 11.3% | -24.3% | ||
| Q4 24 | 29.6% | 4.4% | ||
| Q3 24 | 11.7% | 0.1% | ||
| Q2 24 | 12.8% | -9.2% | ||
| Q1 24 | -7.3% | -16.5% |
| Q4 25 | 3.8% | 1.4% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 6.3% | 2.8% | ||
| Q1 25 | 4.0% | 2.2% | ||
| Q4 24 | 2.7% | 0.8% | ||
| Q3 24 | 1.8% | 0.9% | ||
| Q2 24 | 3.4% | 1.7% | ||
| Q1 24 | 2.5% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | -330.22× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
